在根治性放疗中实施90天死亡率指标需谨慎:基于逾16000例次的人群回顾性分析
该研究从本地电子健康记录提取七年内所有根治性放疗病例并链接癌症登记数据,评估90天死亡率(90DM)及其相关因素。总体90DM为1.25%,随诊断不同在0.20%-5.45%间波动,年龄、治疗年份和诊断与90DM显著相关。作者认为由于人群异质性和低事件率,90DM不能常规作为临床指标,需进一步全国性研究开发稳健指标。
要点
- 根治性放疗总体90DM为1.25%,但随诊断不同在0.20%-5.45%间波动。
- 年龄、治疗年份和诊断与90DM显著相关。
- 90DM因人群异质性和低事件率不宜常规作为临床指标。
核心结论
- 由于显著的人群异质性和低事件率,90DM不能常规采用作为根治性放疗的临床指标。
- 需要进一步全国性研究来开发有意义的稳健指标,以实现适当的中心间比较并推动照护改进。
研究设计与样本
- 回顾性人群为基础的分析,提取七年内所有根治性放疗治疗,并链接癌症登记数据。
- 使用逻辑回归分析90DM率及与结局相关的因素,并回顾性确定死亡原因以进一步刻画90DM的原因。
主要发现
- 总体90DM为1.25%,水平随诊断不同在0.20%-5.45%间广泛变化。
- 多变量逻辑回归显示年龄(OR 1.066,1.043-1.073)、治疗年份(OR 0.900,0.841-0.969)和诊断与90DM显著相关。
- 死亡原因随诊断不同:直肠癌术后占50.0%,头颈癌治疗相关占40.4%,肺癌疾病进展占59.4%。
临床怎么用
- 在将90DM用作中心间比较或服务改进指标时需谨慎,因其受人群异质性和低事件率影响。
- 应关注不同诊断间90DM的显著差异及死亡原因构成,避免单一指标误导质量评价。
局限性
- 研究为单中心回顾性分析,结论外推需谨慎。
- 90DM事件率低且人群异质性大,限制了其作为稳健比较指标的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 90-day mortality (90DM) has been proposed as a clinical indicator in radiotherapy delivered in a curative setting. No large scale assessment has been made. Its value in allowing robust comparisons between centres and facilitating service improvement is unknown. METHODS: All radiotherapy treatments delivered in a curative setting over seven years were extracted from the local electronic health record and linked to cancer registry data. 90DM rates were assessed and factors associated with this outcome were investigated using logistic regression. Cause of death was identified retrospectively further characterising the cause of 90DM. RESULTS: Overall 90DM was 1.25%. Levels varied widely with diagnosis (0.20-5.45%). Age (OR 1.066, 1.043-1.073), year of treatment (OR 0.900, 0.841-0.969) and diagnosis were significantly associated with 90DM on multi-variable logistic regression. Cause of death varied with diagnosis; 50.0% post-operative in rectal cancer, 40.4% treatment-related in head and neck cancer, 59.4% disease progression in lung cancer. CONCLUSION: Despite the drive to report centre level comparative outcomes, this study demonstrates that 90DM cannot be adopted routinely asa clinical indicator due to significant population heterogeneity and low event rates. Further national investigation is needed to develop a meaningful robust indicator to deliver appropriate comparisons and drive improvements in care.
引用
- Spencer K, Ellis R, Birch R, et al. Caution is required in the implementation of 90-day mortality indicators for radiotherapy in a curative setting: A retrospective population-based analysis of over 16,000 episodes. Radiother Oncol. 2017. PMID: 28844331. doi:10.1016/j.radonc.2017.07.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。